Video

Extended Adjuvant Neratinib Therapy for Patients with HER2+ Early Breast Cancer

Author(s):

Joyce O’Shaughnessy, MDVirginia Borges, MD

Joyce O’Shaughnessy, MD, starts a conversation on which patients with HER2+ early breast cancer are the best candidates for extended adjuvant neratinib therapy.

Related Videos
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"
Video 13 - "Treatment Considerations in HER2-Mutated NSCLC"
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"
Video 17 - "Phase 2 ATLEP Trial Results"
Related Content
OncLive On Air
May 30th 2024

Revisit Every OncLive On Air Episode From May 2024

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

breast
May 28th 2024

Neoadjuvant Pembrolizumab/Chemo, Adjuvant Pembrolizumab Boosts OS in High-Risk Early TNBC

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Breast Cancer
May 23rd 2024

Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth

State of the Science Summit - Breast Cancer: Chaired by Suzanne B. Coopey, MD, FACS, and Christie J Hilton, DO
May 23rd 2024

State of the Science Summit - Breast Cancer: Chaired by Suzanne B. Coopey, MD, FACS, and Christie J Hilton, DO